2018 Autumn Conference
15 – 16 October, 2018 // The Ritz Carlton, Marina del Rey, CA
Distinguished Poster Award Recipients: |
||
| Development and Validation of a patient-reported outcomes symptom measure (ePRO) for assessing Awareness of Insight in Schizophrenia: Preliminary Findings (Lucic) Deep Learning-Based Human Activity Recognition for Continuous Activity and Gesture Monitoring for Schizophrenia Patients with Negative Symptoms (Umbricht) |
||
| All Poster PDFs and Abstracts are available at the end of the first day. | ||
Day 1 (15 October 2018) |
||
| Presidential Welcome | C Canuso slides video |
|
| Innovative Uses of Technology for Measuring Outcomes in Clinical Trials (Part 1) | Chairs: P Harvey T Farchione |
|
| Introduction | T Farchione slides video |
|
| Landscape of technology utilization of outcomes assessment in neuropsychiatric disorders | P Harvey slides video |
|
| Technology enabled clinical endpoint innovation: Foundational concepts and pathway for development | M Walton slides video |
|
| Devil, details, and data: Measurement models and analysis strategies for novel technology-based clinical outcome assessments | B Bilder slides video |
|
| The path to FDA acceptance of technological strategies | M Davis slides video |
|
| Panel Discussion | A Kalali – Facilitator Discussants – A Atkins slidesR Curiel slidesK Granger* H Mahncke slidesR Moore slides video |
|
| Innovative Uses of Technology for Measuring Outcomes in Clinical Trials (Part 2) | Chairs: R Keefe M Davis |
|
| Introduction | R Keefe video |
|
| Technologies for measuring cognition in clinical trials | S Arnerić slides video |
|
| Statistical methods for wearable technology in CNS trials | A Potter slides video |
|
| Balancing the thrill of innovation and the fear of humiliation in choosing technology for CNS trials | K Daniels slides video |
|
| Validating digital biomarkers measured by patients’ own smart devices: Case studies from Parkinson’s disease and Multiple Sclerosis | C Gossens slides video |
|
| Advances in assessment technologies: Clinical informatics considerations | D Warfield slides video |
|
| Panel discussion with regulatory comment | T Farchione – Facilitator Discussants – M Davis V Mantua * L Pani slidesA Potter M Walton D Warfield video |
|
| Poster Session/Reception | Poster PDFs and Abstracts | |
Day 2 (16 October 2018) |
||
Workshop Breakfasts |
||
| Algorithms/Rules to Identify Clinical Inconsistency in the Use of Rating Scales in CNS RCTS | Chair: N Schooler Summary |
|
| Autism Spectrum Disorder | Chairs: T Farchione, V Mantua, C Arango Molecular Targets Endpoints Trial Design Biomarkers: Pandina Dawson-McPartland |
|
| Cognitive Trajectories in Schizophrenia | Chairs: P Harvey, K Granger Summary slides |
|
| Orphan Diseases | Chairs: J Busner, R Anand Summary |
|
| Prevention Trials in Alzheimer’s Disease | Chair: H Posner Summary-Slides |
|
Parallel Sessions |
||
| Session A: The Promise and Challenges of Gene Therapy for CNS Disorders |
Chairs: B Ravina W Dunn |
|
| Introduction | W Dunn slides video |
|
| Gene therapy: The basics | M Kay slides video |
|
| Gene therapy: Early clinical development challenges | S Hersch** slides |
|
| Clinical development of gene therapies: Safety evaluation and monitoring | L Xu slides video |
|
| Clinical trial paradigms in gene therapy | B Ravina slides video |
|
| Panel Discussion | Speakers video |
|
| Session B: Biomarkers in Psychiatric Drug Development: An Update | Chair: D Goff |
|
| Introduction | D Goff video |
|
| New computational approaches for characterizing clinical phenotypes and analyzing biomarkers | I Galatzer-Levy slides video |
|
| Using machine learning approaches to identify imaging markers that predict antidepressant response | A Etkin slides |
|
| Functional NMDA receptor-based target engagement biomarkers for schizophrenia research | D Javitt slides video |
|
| Imaging biomarkers for the assessment of placebo response | A Anderson slides video |
|
| Panel/Audience Discussion | D Umbricht – Discussant slides video |
|
| Novel Technologies to Identify Underlying Molecular Pathology in Neurodegeneration | Chair: H Soares |
|
| Introduction | H Soares video |
|
| Mixed pathologies in dementia and movement disorders | E Lee slides video |
|
| CSF assays to detect patients with seeding-competent aggregates of Abeta, tau and alpha-synuclein: Applications to identify mixed pathologies in AD, DLB, FTD and PD | C Soto** slides |
|
| PET neuroimaging approaches to characterizing underlying molecular pathology in neurodegenerative disease | S Landau slides video |
|
| Clinical trial design opportunities for mixed pathologies in neurodegenerative disorders | N Mendonca** | |
| Panel Discussion | Soares – Facilitator slidesV Mantua* Speakers video |
|
| Meeting Adjourned |
||
| *Presentation not released **Video not released |
||